The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | The current status of liso-cel in CLL and updates from the TRANSCEND-CLL-004 trial
William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly comments on the current status of lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia (CLL), highlighting results from the ongoing TRANSCEND-CLL-004 trial (NCT03331198). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
